SC 13G/A: Beam Therapeutics Inc.

AI Summary

SC 13G/A filing by Beam Therapeutics Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.01 — ame of Issuer) Common Stock par value $0.01 per share (Title of Class of Securiti

Filing Documents

• arch-sch13g_18793.htm (SC 13G/A) — 269KB
• 0001072613-24-000251.txt ( ) — 271KB

(a)

Item 1(a). Name of Issuer Beam Therapeutics, Inc. (the “Issuer”).

(b)

Item 1(b). Address of Issuer's Principal Executive Offices 238 Main Street, Cambridge, MA 02142

(a)

Item 2(a). Name of Person Filing ARCH Venture Fund IX, L.P. (“AVF IX”); ARCH Venture Partners IX, L.P. (“AVP IX LP”); ARCH Venture Partners IX, LLC (“AVP IX LLC”); ARCH Venture Fund IX Overage, L.P. (“AVF IX Overage”); ARCH Venture Partners IX Overage, L.P. (“AVP IX Overage GP”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the “Reporting Persons”.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence 8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

(c)

Item 2(c). Citizenship Each of AVF IX, AVP IX LP, AVF IX Overage and AVP IX Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

(d)

Item 2(d). Title of Class of Securities Common stock, par value $0.01 per share.

(e)

Item 2(e). CUSIP Number 07373V105 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not Applicable. CUSIP No. 07373V105 13G Page 11 of 15 Pages Item 4. (a) Amount beneficially owned: AVF IX is the record owner of 2,721,520 shares of Common Stock (the “AVF IX Shares”) as of December 31, 2023. AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Shares. AVF IX Overage is the record owner of 2,721,519 shares of Common Stock (the “AVF IX Overage Shares”; combined with the AVF IX Shares, the “Record Shares”) as of December 31, 2023. AVP IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the AVF IX Overage Shares. AVP IX LLC, as the sole general partner of AVP IX LP and AVP IX Overage GP, may be deemed to beneficially own the Record Shares. As managing directors of AVP IX LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the Record Shares. In addition, as of December 31, 2023, Crandell is a holder of 33,058 Shares of Common Stock, Bybee and his related trusts are the holder of 10,498 shares of Common Stock, and Nelsen and his related trusts are the holder of 60,615 shares of Common Stock. (b) Percent of class: See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person is based upon 81,504,057 shares of common stock outstanding as of November 1, 2023, as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 8, 2023. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See line 5 of the cover sheets. (ii) Shared power to vote or to direct the vote: See line 6 of the cover sheets. (iii) Sole power to dispose or to direct the disposition: See line 7 of